4D Molecular Therapeutics Competitors

4D Molecular Therapeutics (NASDAQ:FDMT) and Seer (NASDAQ:SEER) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for 4D Molecular Therapeutics and Seer, as provided by MarketBeat.

4D Molecular Therapeutics presently has a consensus price target of $45.50, indicating a potential upside of 37.05%. Seer has a consensus price target of $68.00, indicating a potential upside of 33.73%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe 4D Molecular Therapeutics is more favorable than Seer.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and Seer's gross revenue, earnings per share and valuation.

Profitability

This table compares 4D Molecular Therapeutics and Seer's net margins, return on equity and return on assets.

Summary

4D Molecular Therapeutics beats Seer on 2 of the 2 factors compared between the two stocks.

4D Molecular Therapeutics (NASDAQ:FDMT) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for 4D Molecular Therapeutics and Nuvation Bio, as provided by MarketBeat.

4D Molecular Therapeutics presently has a consensus price target of $45.50, indicating a potential upside of 37.05%. Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 73.48%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Nuvation Bio is more favorable than 4D Molecular Therapeutics.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and Nuvation Bio's gross revenue, earnings per share and valuation.

Profitability

This table compares 4D Molecular Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

Summary

Nuvation Bio beats 4D Molecular Therapeutics on 3 of the 3 factors compared between the two stocks.

4D Molecular Therapeutics (NASDAQ:FDMT) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Profitability

This table compares 4D Molecular Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and ImmunityBio's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for 4D Molecular Therapeutics and ImmunityBio, as provided by MarketBeat.

4D Molecular Therapeutics presently has a consensus price target of $45.50, indicating a potential upside of 37.05%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 43.84%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than 4D Molecular Therapeutics.

Summary

ImmunityBio beats 4D Molecular Therapeutics on 2 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Immunocore and 4D Molecular Therapeutics, as reported by MarketBeat.

Immunocore presently has a consensus price target of $54.3333, indicating a potential upside of 42.05%. 4D Molecular Therapeutics has a consensus price target of $45.50, indicating a potential upside of 37.05%. Given Immunocore's higher probable upside, equities research analysts plainly believe Immunocore is more favorable than 4D Molecular Therapeutics.

Profitability

This table compares Immunocore and 4D Molecular Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Immunocore and 4D Molecular Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Summary

Immunocore beats 4D Molecular Therapeutics on 1 of the 1 factors compared between the two stocks.

4D Molecular Therapeutics (NASDAQ:FDMT) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for 4D Molecular Therapeutics and BioAtla, as reported by MarketBeat.com.

4D Molecular Therapeutics presently has a consensus target price of $45.50, indicating a potential upside of 37.05%. BioAtla has a consensus target price of $58.00, indicating a potential upside of 21.49%. Given 4D Molecular Therapeutics' higher possible upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than BioAtla.

Valuation & Earnings

This table compares 4D Molecular Therapeutics and BioAtla's revenue, earnings per share and valuation.

Profitability

This table compares 4D Molecular Therapeutics and BioAtla's net margins, return on equity and return on assets.

Summary

BioAtla beats 4D Molecular Therapeutics on 2 of the 3 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Valuation and Earnings

This table compares Cullinan Oncology and 4D Molecular Therapeutics' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Cullinan Oncology and 4D Molecular Therapeutics, as reported by MarketBeat.

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 37.07%. 4D Molecular Therapeutics has a consensus target price of $45.50, suggesting a potential upside of 37.05%. Given Cullinan Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Cullinan Oncology is more favorable than 4D Molecular Therapeutics.

Profitability

This table compares Cullinan Oncology and 4D Molecular Therapeutics' net margins, return on equity and return on assets.

Summary

Cullinan Oncology beats 4D Molecular Therapeutics on 3 of the 3 factors compared between the two stocks.